Investorideas.com

Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS


 


investorideas.com - A Leading Global Investor Website for Biotech Industry Stocks

Investing in biotechnology stocks, pharma, medical technology and telemedicine has never been more exciting for investors with all of the new breakthroughs in technology and health. Let Investor Ideas help you find your next big idea in the sector with our free stock directories and news alerts. Don't miss out on the chance to invest in the future of healthcare and technology!

Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech Stocks

Investorideas Featured Company: Aethlon Medical, Inc. (NASDAQ: AEMD)

Aethlon Medical, Inc. (NASDAQ: AEMD) is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Get news alerts on this company!

Biotech News

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) to Present at the Emerging Growth Conference on February 19, 2025
SAN DIEGO - February 13, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, is pleased to announce that it has been invited to present on the Emerging Growth Conference on February 19, 2025.

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Announces Financial Results for the Fiscal Third Quarter Ended December 31, 2024 and Provides Corporate Update
SAN DIEGO - February 12, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal third quarter ended December 31, 2024 and provided an update on recent developments.

Tivic Health Systems, Inc. (Nasdaq: TIVC) Makes NASDSAQ Top Gainers List on Licensing News
February 12, 2025 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Tivic Health Systems, Inc., (Nasdaq: TIVC), a diversified therapeutics company harnessing the power of the immune and autonomic nervous systems to fight disease and restore health.

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2025
SAN DIEGO - February 5, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life threatening infectious diseases, today announced that it will issue financial results for its fiscal third quarter ended December 31, 2024, at 4:15 p.m. ET on Wednesday, February 12, 2025.

News on Alternative monoclonal antibody for treatment of COVID-19 Spikes Invivyd, Inc. (Nasdaq: IVVD) to Top Gainer List
February 3, 2025 (Investorideas.com Newswire) Investorideas.com, a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Invivyd, Inc. (Nasdaq: IVVD) is a biopharmaceutical company devoted to delivering protection from serious viral infectious diseases.

Medical Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Cancer Clinical Trial update
January 29, 2025 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including biotech and medical tech stocks reports on trading and news for Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases.

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Treats First Patient in Australian Hemopurifier Cancer Trial
SAN DIEGO - January 29, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: the treatment of the first patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier.

Healthcare Investors Take Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) to NASDAQ Top Percentage Gainers List
January 17, 2025 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including biotech and medical stocks reports on trading and news for Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD), a leader in minimally invasive Microwave Ablation (MWA) technology.

Biomedical Stock Biomerica Inc. (NASDAQ: BMRA) Makes NASDAQ TOP Gainer List on UAE Ministry of Health and Prevention Approval
January 16, 2025 (Investorideas.com Newswire) Investorideas.com, a go-to platform for big investing ideas for stock traders, including biotech and medical stocks reports on trading and news for Biomerica, Inc.(Nasdaq: BMRA), a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases.

Pharma Stock SciSparc Ltd. (Nasdaq: SPRC) Soars on Psychedelic News
January 6, 2025 (Investorideas.com Newswire) Investorideas.com, a go-to platform for big investing ideas for stock traders, including biotech and psycadelic stocks reports on trading and news for SciSparc Ltd. (Nasdaq: SPRC), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Other Ideas - Guest Posts and / or sponsored financial content

Learn how to be published on our site: Buy a guest post on Investorideas.com

Choosing the Right Dosage Form: Tablets, Capsules, or Liquids - January 30, 2025

Are Biohazard Remediation Services Worth Investing In? - November 29, 2024

Unleash Your Potential: Mojo Trek's Personalized Approach to Healthtech Recruitment - November 29, 2024

The Intersection of Business and Public Health: Why an MBA is Essential for Health Administrators - July 25, 2024

Nick Oberheiden and the Impella Heart Pump Cases - June 28, 2024

An Investor's Guide to Qualitative Analysis of Biotech Firms - June 18, 2024

How Healthcare Bookkeeping Services Elevate Your Business - March 27, 2024

The Rise of Mobile Applications in Healthcare and Medicine - September 5, 2023

How to Prove Wrongful Death - February 1, 2022

Healthcare Supply Chain Management Software - November 29, 2021

Overview of Biotech Stocks - What Could Happen by the End of 2021? - November 3, 2021

Consider Investing In These Disruptive Medical Companies In 2021 - April 16, 2021

Resources for Physicians and Medical Practices - December 31, 2020

Lockdown Part 2: The South African Economy and the Rand - December 15, 2020

How to Get Into Canada during COVID - November 30, 2020

The Impact of Gynecomastia on Your Mental Health and How to Deal With the Condition - September 8, 2020

Does Income Protection Cover Me for a COVID Redundancy? - August 10, 2020

Everything You Need to Know About Investing in Healthcare Stocks - March 30, 2020

The Rise Of The At-Home Testing Market - January 16, 2020

Why Do You Need Birth Injury Lawyer and How They Can Help You? - October 2, 2019

Biotech News from Newsfile

Restart Life Announces Key Business Updates
Vancouver, British Columbia--(Newsfile Corp. - February 13, 2025) - Restart Life Science Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSD) ("Restart Life" or the "Company") is pleased to provide an update on recent developments under the leadership of its newly appointed CEO. Steve Loutskou, a serial entrepreneur, is dedicated to driving shareholder value through sustainable growth and expanding opportunities for the Company."I would like to thank our shareholders for their support in our private...

Kiora Pharmaceuticals Secures U.S. Composition-of-Matter Patent Expanding Protection of Its Anti-Inflammatory Compound KIO-104
Encinitas, California--(Newsfile Corp. - February 13, 2025) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) today announced that the U.S. Patent and Trademark Office has issued a composition-of-matter patent (US-12209073-B2) on a specific crystalline form, or polymorph, of KIO-104. KIO-104 is a novel, non-steroidal anti-inflammatory, small molecule inhibitor of dihydroorotate dehydrogenase (DHODH). A Phase 2 clinical trial of KIO-104 for the treatment of retinal inflammation is expected to begin in...

Aires Launches the Aires Certified Spaces (ACS) Standard for Creating Authorized EMF-Friendly Physical Spaces
Enables Aires to access a whole new, large-scale physical-spaces marketACS marks initial step toward Aires entering massive commercial B2B market1Supports expanding brand awareness & growing sales through mass market exposureToronto, Ontario--(Newsfile Corp. - February 13, 2025) - American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) ("Aires" or the "Company"), a pioneer in advanced technology designed to protect against electromagnetic field (EMF) radiation and optimize human health, today officially...

InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update
Vancouver, British Columbia--(Newsfile Corp. - February 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the second quarter of the fiscal year 2025 which ended December 31, 2024.The Company's full financial statements and related MD&A for the first quarter ended December 31, 2024,...

BioHarvest Sciences to Present at WeBull Consumer Stocks Webinar on February 18
Vancouver, British Columbia and Rehovot, Israel--(Newsfile Corp. - February 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (CSE: BHSC) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that management has been invited to present at the WeBull Consumer Stocks Virtual Webinar taking place on February 18, 2025.CEO Ilan Sobel is scheduled to present at the event. Following the webinar, a replay link to the...

Subscribe to Biotech News